Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)

Courtney D Dinardo,Hartmut Döhner,Amir T Fathi,Vickie Zhang,Andre C Schuh,Anthony S Stein,Xiwei Wang,Jing Gong,Denice Hickman,Emmanuel Raffoux,Hagop M Kantarjian,Giovanni Martinelli,Stéphane De Botton,Olga Frankfurt,Eytan M Stein,Stephanie M Kapsalis,Paresh Vyas,Thomas Winkler,Amer M Zeidan ,Richard Stone ,Peter Tan ,Du Lam ,Scott R Daigle

doi:10.1016/j.clml.2019.07.090

Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)

Courtney D Dinardo, Hartmut Döhner + Show 21 more

https://doi.org/10.1016/j.clml.2019.07.090

Copy DOI

Journal: Clinical Lymphoma Myeloma and Leukemia	Publication Date: Aug 28, 2019
Citations: 3

Affiliation: The University of Texas MD Anderson Cancer Center, University Hospital Ulm, Massachusetts General Hospital, Agios Pharmaceuticals (United States), Princess Margaret Cancer Centre, City Of Hope National Medical Center, Hôpital Saint-Louis, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Istituti di Ricovero e Cura a Carattere Scientifico, Institut Gustave Roussy, Northwestern University, Memorial Sloan Kettering Cancer Center, University of Oxford, Yale Cancer Center, Dana-Farber Cancer Institute, Royal Perth Hospital

#ND AML #Azacitidine + Show 6 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Clinical Lymphoma Myeloma and Leukemia

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.